http://www.nytimes.com/2010/10/29/health/policy/29drug.html?_r=1&hpNot having too much luck at the moment over at vivus!Just goes to show they should have got their act together on the deal with Acrux, might have had something in the pipes still!
I88 Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”
TLX Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
